We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.
- Authors
Chayama, Kazuaki; Hayes, C Nelson; Abe, Hiromi; Miki, Daiki; Ochi, Hidenori; Karino, Yoshiyasu; Toyota, Joji; Nakamura, Yusuke; Kamatani, Naoyuki; Sezaki, Hitomi; Kobayashi, Mariko; Akuta, Norio; Suzuki, Fumitaka; Kumada, Hiromitsu
- Abstract
Pegylated interferon, ribavirin, and telaprevir triple therapy is a new strategy expected to eradicate the hepatitis C virus (HCV) even in patients infected with difficult-to-treat genotype 1 strains, although adverse effects, such as anemia and rash, are frequent.
- Publication
The Journal of infectious diseases, 2011, Vol 204, Issue 1, p84
- ISSN
1537-6613
- Publication type
Journal Article
- DOI
10.1093/infdis/jir210